Phaseline

Companies › Dong Wha Pharmaceutical

Dong Wha Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pioglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 4Type2diabetes–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06875193PioglitazonePhase 4Type2diabetesMetabolic and endocrineDec 2025

Targets

PPARG (1)

Companies with the same targets

Zydus Therapeutics Flare Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Inventiva Pharma

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.